Mirati Therapeutics, Inc.
MTA-Cooperative PRMT5 Inhibitors
Last updated:
Abstract:
The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
Status:
Application
Type:
Utility
Filling date:
11 Sep 2020
Issue date:
18 Mar 2021